Preface

Open Access
Publisher Website
Google Scholar
Abstract
Dual antiplatelet therapy has become an essential tool in the treatment of acute coronary syndromes and an adjunctive therapy in percutaneous coronary intervention. Many patients have received the benefit of this strategy. However, pending issues concerning efficacy and safety in terms of prevention of thrombosis and bleeding still remain. In this issue, important new perspectives on novel approaches to the inhibition of platelet aggregation by action on P2Y12 platelet receptor are offered, so that the benefits of clopidogrel, without its associated risks can be extended to more patients.

This publication has 0 references indexed in Scilit: